BRAVENKnow what's real. Now.
Tuesday, August 18, 2026
World2 outlets covering this

CSL FY26 slides: reset year with $7.1B impairments, 5% growth ahead

First publishedAug 17, 02:16 UTC
Last updatedAug 18, 04:28 UTC · 7m ago
11 outletInvesting.com · Company News11 outletInvesting.com · Company News
Investing.com · Company News5Australian Clinical Labs FY26 slides: margins expand despite revenue headwindsOpen ↗Investing.com · Company News5CSL FY26 slides: reset year with $7.1B impairments, 5% growth aheadOpen ↗
2 outlets over time — hover a bar for its window & outletslast updated
CSL FY26 slides: reset year with $7.1B impairments, 5% growth ahead - image 1CSL FY26 slides: reset year with $7.1B impairments, 5% growth ahead - image 2
1 / 2
● Story signals

How strong is this topic?

5.6/10Significanceimpact & urgency
5.0/10Source trustoutlet authority
2Outletsindependent sources

Significance weighs impact, urgency & coverage breadth · Source trust is the outlets' average authority · more outlets means a more confirmed story.

Answer

CSL Limited (ASX:CSL) presented its fiscal year 2026 full-year results on August 18, 2026, describing the period as a "reset year" characterized by strategic transformation initiatives and significant non-cash charges. The Australian biotech and plasma specialist reported a statutory net loss of $2.6 billion, driven by $7.1 billion in impairments and restructuring costs, even as underlying operations remained profitable and cash generative.

Reported by 2 outlets — Investing.com · Company News. See all sources ↓

CSL Limited (ASX:CSL) presented its fiscal year 2026 full-year results on August 18, 2026, describing the period as a "reset year" characterized by strategic transformation initiatives and significant non-cash charges. The Australian biotech and plasma specialist reported a statutory net loss of $2.6 billion, driven by $7.1 billion in impairments and restructuring costs, even as underlying operations remained profitable and cash generative. The company’s shares surged 16.4% to $156.68 following the announcement, as investors focused on forward guidance calling for approximately 5% underlying profit growth in FY27. Interim CEO Gordon Naylor emphasized that the company has been "positioned to return to sustainable growth" following operational simplification, enhanced commercial execution, and a comprehensive transformation program that delivered $176 million in cost savings during the year.

Read the full report at Investing.com · Company News ↗

Why it matters

2 outlets are covering this world story — one to watch as reporting develops.

In brief
What's the story?
CSL Limited (ASX:CSL) presented its fiscal year 2026 full-year results on August 18, 2026, describing the period as a "reset year" characterized by strategic transformation initiatives and significant non-cash charges. The Australian biotech and plasma specialist reported a statutory net loss of $2.6 billion, driven by $7.1 billion in impairments and restructuring costs, even as underlying operations remained profitable and cash generative.
How widely is it covered?
2 outlets, average source rating 5.0/10.
When was it last updated?
7m ago.
Different angles across outlets
Coverage map

How outlets are framing the same story

Here's how each outlet is covering the story — compare their headlines and timing at a glance.

  • Coverage card1 outlet
    1Coverage
    Scouting report

    CSL FY26 slides: reset year with $7.1B impairments, 5% growth ahead

    Sources1
    TypeCoverage
    Investing.com · Company News
Sources (2)
Avg source rating 5.0/10
Processing cluster
A1A2A3B1B2B3
Share this article
X / TwitterLinkedInWhatsApp
Summarize with AI (opens AI chat with article URL · Gemini: prompt copied to clipboard)
GPTPerplexityGeminiClaude